Key clinical point: A phase 1 first-in-human study demonstrated synthetic T-cell receptor and antigen receptor technical feasibility, clinical safety and efficacy in treating CD19+ relapsed/refractory B-cell acute lymphoblastic leukemia.

Major finding: On day 14 following transplant, 100% had achieved a minimal residual disease–negative complete response/CR with incomplete hematologic recovery.

Study details: The first-in-human study included 18 CD19+ relapsed/refractory B-cell acute lymphoblastic leukemia patients, with a median bone marrow blast level pre–CAR T of 15.3% (0.5-90.5%).

Disclosures: Dr. Lu reported having no relevant conflicts of interest.